•
1 4

ONC Alert oral cancer RAPID TEST

$80.50 USD
$94.71 USD
$80.50 USD

BENEFITS

  • 5x-9x increased risk
  • 5% of daily users develop lesions
  • 9x-30x increased risk
  • >50% of oral cancers are related to human papillomavirus (HPV)

  • OncAlert Oral Cancer

    The OncAlert Oral Cancer product line is comprised of proprietary tests that detect CD44 and total protein. These tests are optimized for easy use by collecting samples via an oral saline rinse. The test results, along with other clinical factors, can aid in the early diagnosis of oral cancer. Healthcare providers can get a simple and accurate assessment to aid in the early detection of oral cancer (including oral and oropharyngeal cancer) potentially before lesions are visible. OncAlert RAPID test provides a qualitative result at the point of care, reporting either normal or elevated levels of oral cancer biomarkers. The test are technologically advanced and highly accurate methods to aid in the early detection of oral cancer including oral and oropharyngeal cancer.

The OncAlert Oral Cancer product line is comprised of proprietary tests that detect CD44 and total protein. These tests are optimized for easy use by collecting samples via an oral saline rinse. The test results, along with other clinical factors, can aid in the early diagnosis of oral cancer. Healthcare providers can get a simple and accurate assessment to aid in the early detection of oral cancer (including oral and oropharyngeal cancer) potentially before lesions are visible. OncAlert RAPID test provides a qualitative result at the point of care, reporting either normal or elevated levels of oral cancer biomarkers. The test are technologically advanced and highly accurate methods to aid in the early detection of oral cancer including oral and oropharyngeal cancer.

The OncAlert Oral Cancer product line is comprised of proprietary tests that detect CD44 and total protein. These tests are optimized for easy use by collecting samples via an oral saline rinse. The test results, along with other clinical factors, can aid in the early diagnosis of oral cancer. Healthcare providers can get a simple and accurate assessment to aid in the early detection of oral cancer (including oral and oropharyngeal cancer) potentially before lesions are visible. OncAlert RAPID test provides a qualitative result at the point of care, reporting either normal or elevated levels of oral cancer biomarkers. The test are technologically advanced and highly accurate methods to aid in the early detection of oral cancer including oral and oropharyngeal cancer.